News and Updates

Intensity Therapeutics has resumed its INVINCIBLE-4 Phase 2 trial for triple-negative breast cancer. Discover the latest on this innovative cancer study.

The clinical trials market is set to hit $176B by 2030. Discover how AI and decentralized research models are accelerating drug development worldwide.

The FDA has authorized Atrium’s IND application for ATR 1072. Learn about this new clinical trial milestone and the future of this therapeutic development.

Sound Pharmaceuticals has wrapped up enrollment for its Phase 3 SPI-1005 trial, targeting new treatments for sensorineural hearing loss and Meniere’s disease.

Researchers report promising safety and biomarker results in a Phase 1 trial for a new siRNA-based treatment targeting SOD1-associated ALS.

Vietnam’s pharma sector is set to exceed $10B as aging demographics and new regulatory reforms spark rapid growth in the regional healthcare market.

Over half of all clinical trial sites struggle with patient loss due to inefficiencies. Discover the operational fixes needed to boost retention and R&D.

ORIC Pharmaceuticals has launched the Phase 3 Himalayas-1 trial, testing rinzimetostat as a targeted treatment for metastatic castration-resistant prostate cancer.

New clinical trial data shows the combination of sac-TMT and pembrolizumab hits primary endpoints for patients with PD-L1-negative NSCLC. Read more here.

Discover how clinical trial simulation and digital twins are slashing R&D costs and accelerating drug development by replacing traditional research models.